Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder

Journal of Urology

Volumn 175, Issue 3, 2006, Pages 875-880

  Hauser Kronberger, C ^a   Peham, K ^a   Grall, J ^a   Rausch, W ^b   Hutarew, G ^a   Dietze, O ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b Department of Pathology   (Austria)

Author keywords

Bladder neoplasms; Epidermal growth factor receptor related protein; Human; Immunohistochemistry; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CHROMOSOME 17; CHROMOSOME ABERRATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; HUMANS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; URINARY BLADDER NEOPLASMS;

EID: 32044465767     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00411-8     Document Type: Article

References (19)

1. H.E. Zhau, X. Zhang, A.C. von Eschenbach, K. Scorsone, R.J. Babaian, J.Y. Ro Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer Mol Carcinog 3 1990 254
2. G. Sauter, H. Moch, D. Moore, P. Carroll, R. Kerschmann, K. Chew Heterogeneity of erbB-2 gene amplification in bladder cancer Cancer Res 53 1993 2199
3. R. Gandour-Edwards, P.N. Lara Jr., A.K. Folkins, J.M. LaSalle, L. Beckett, Y. Li Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95 2002 1009
4. S. Kruger, G. Weitsch, H. Buttner, A. Matthiensen, T. Bohmer, T. Marquardt HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder prognostic implications Int J Cancer 102 2002 514
5. K. Wester, A. Sjostrom, M. de la Torre, J. Carlsson, P.U. Malmstrom HER-2-a possible target for therapy of metastatic urinary bladder carcinoma Acta Oncol 41 2002 282
6. Z. Latif, A.D. Watters, I. Dunn, K. Grigor, M.A. Underwood, J.M. Bartlett HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder a role for anti-HER2 therapy? Eur J Cancer 40 2004 56
7. G. de Pinieux, D. Colin, A. Vincent-Salomon, J. Couturier, D. Amsellem-Ouazana, P. Beuzeboc Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma Virchows Arch 444 2004 415
8. J. Bartlett, E. Mallon, T. Cooke The clinical evaluation of HER-2 status which test to use? J Pathol 199 2003 411
9. M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno Current perspectives on HER2 testing a review of national testing guidelines Mod Pathol 16 2003 173
10. M. Tanner, D. Gancberg, A. Di Leo, D. Larsimont, G. Rouas, M.J. Piccart Chromogenic in situ hybridization a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am J Pathol 157 2000 1467
11. N. Dandachi, O. Dietze, C. Hauser-Kronberger Chromogenic in situ hybridization a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma Lab Invest 82 2002 1007
12. C. Hauser-Kronberger, N. Dandachi Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer J Mol Histol 35 2004 647
13. R.R. Tubbs, J. Pettay, P. Roche, M.H. Stoler, R. Jenkins, J. Myles Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH) a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression J Mol Diagn 2 2000 78
14. J. Zhao, R. Wu, A. Au, A. Marquez, Y. Yu, Z. Shi Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma Mod Pathol 15 2002 657
15. L. Arnould, Y. Denoux, G. MacGrogan, F. Penault-Llorca, M. Fiche, I. Treilleux Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer Br J Cancer 88 2003 1587
16. J. Isola, M. Tanner, A. Forsyth, T.G. Cooke, A.D. Watters, J.M. Bartlett Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization Clin Cancer Res 10 2004 4793
17. M. Dowsett, J. Bartlett, I.O. Ellis, J. Salter, M. Hills, E. Mallon Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 2003 418
18. M.F. Press, L. Bernstein, P.A. Thomas, L.F. Meisner, J.Y. Zhou, Y. Ma HER-2/neu gene amplification characterized by fluorescence in situ hybridization poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894
19. D. Gupta, L.P. Middleton, M.J. Whitaker, J. Abrams Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer Am J Clin Pathol 119 2003 381